PRAMEF1 Inhibitors
PRAMEF1 inhibitors belong to a class of compounds that target the PRAME family member 1 (PRAMEF1) protein, a member of the PRAME (Preferentially Expressed Antigen in Melanoma) family of proteins. The PRAMEF1 protein is known for its role in regulating gene expression by acting as a transcriptional repressor, binding to various regulatory sequences of DNA to control the expression of certain genes. These proteins are involved in complex interactions within the cellular environment, particularly in processes such as cell differentiation, proliferation, and apoptosis. PRAMEF1 is unique within its family due to its specific structural motifs and binding domains, which contribute to its distinct regulatory role in the cell. Inhibitors of PRAMEF1 are designed to interfere with these interactions, effectively blocking the ability of PRAMEF1 to repress its target genes.
Chemically, PRAMEF1 inhibitors are often characterized by specific binding affinities to the PRAMEF1 protein's active or regulatory sites, inhibiting its function in gene repression. These inhibitors may work by either directly binding to the protein, preventing its interaction with DNA, or by disrupting the protein-protein interactions essential for PRAMEF1's regulatory roles. The structure-activity relationships (SAR) of PRAMEF1 inhibitors are a significant area of study, focusing on how small changes in molecular structure can affect binding strength, specificity, and inhibition efficacy. The understanding of the precise molecular mechanisms behind PRAMEF1 inhibition involves advanced biochemical and structural biology techniques, such as crystallography and molecular docking studies, which are used to characterize the inhibitor's interaction with the protein's active site. These inhibitors are valuable in research settings for probing the functional biology of the PRAMEF1 protein and its broader role in cellular regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, through its DNA demethylating action, could potentially reactivate tumor suppressor genes while concurrently downregulating oncogene expression, including that of PRAMEF1, by altering the methylation status of its promoter region. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid may lead to the acetylation of histones associated with the PRAMEF1 gene, potentially causing a tight chromatin conformation that decreases accessibility for transcription machinery, thus decreasing PRAMEF1 expression. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
By inhibiting aldehyde dehydrogenase, Disulfiram might create an intracellular environment that disrupts the function of transcription factors necessary for PRAMEF1 transcription, leading to a decrease in PRAMEF1 mRNA synthesis. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin may downregulate the expression of PRAMEF1 by hindering the activation of NF-κB, a transcription factor known to enhance the transcription of various genes, including potentially those involved in cancer progression like PRAMEF1. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol could downregulate PRAMEF1 by activating sirtuins, which may lead to the deacetylation of histones at the PRAMEF1 locus, resulting in a condensed chromatin state less conducive to gene transcription. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $150.00 $286.00 $479.00 $1299.00 $8299.00 $915.00 | 22 | |
DL-Sulforaphane might reduce PRAMEF1 expression by inducing histone deacetylase, which could remove acetyl groups from histones near the PRAMEF1 gene, leading to chromatin condensation and a subsequent decrease in PRAMEF1 gene expression. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin could decrease PRAMEF1 expression by inhibiting kinases involved in signal transduction pathways that promote transcription of growth-promoting genes, including potentially PRAMEF1. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid may downregulate PRAMEF1 by binding to retinoid receptors which can alter the transcriptional control of genes involved in cell differentiation and proliferation, potentially including PRAMEF1. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate could inhibit the expression of PRAMEF1 by disrupting folate metabolism, leading to a reduction of methionine and subsequent hypomethylation of DNA, which may result in the downregulation of genes involved in cell growth, such as PRAMEF1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may inhibit PRAMEF1 expression by specifically blocking mTOR pathway signaling, which is critical for the translation of many oncogenic proteins and could play a role in the synthesis of PRAMEF1. | ||||||